Annual report pursuant to Section 13 and 15(d)

Document and Entity Information

v3.23.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Mar. 22, 2023
Jun. 30, 2022
Cover [Abstract]        
Document Type 10-K      
Amendment Flag false      
Document Period End Date Dec. 31, 2022      
Document Fiscal Year Focus 2022      
Document Fiscal Period Focus FY      
Document Annual Report true      
Document Transition Report false      
Trading Symbol MAIA      
Entity Incorporation State Country Code DE      
Entity Registrant Name MAIA BIOTECHNOLOGY, INC.      
Entity Central Index Key 0001878313      
Current Fiscal Year End Date --12-31      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Well-known Seasoned Issuer No      
Entity Voluntary Filers No      
Entity Filer Category Non-accelerated Filer      
Entity Shell Company false      
Entity Small Business true      
Entity Emerging Growth Company true      
Entity Ex Transition Period false      
Entity File Number 001-41455      
Entity Tax Identification Number 83-1495913      
Entity Address Address Line1 444 West Lake Street      
Entity Address, Address Line Two Suite 1700      
Entity Address City Or Town Chicago      
Entity Address State Or Province IL      
Entity Address Postal Zip Code 06060      
City Area Code 312      
Local Phone Number 416-8592      
Entity Common Stock, Shares Outstanding     10,996,404  
Entity Public Float       $ 0
ICFR Auditor Attestation Flag false      
Security12b Title Common Stock, $0.0001 par value per share      
Security Exchange Name NYSE      
Auditor Firm ID 248 274    
Auditor Name GRANT THORNTON LLP EISNERAMPER LLP    
Auditor Location Charlotte, North Carolina Iselin, New Jersey    
Documents Incorporated by Reference

Portions of the registrant’s definitive proxy statement for the annual stockholder meeting to be held in 2023 are incorporated by reference into Part III of this Annual Report on Form 10-K as noted herein. The registrant intends to file its proxy statement within 120 days after its fiscal year end.